ARCA biopharma competitors

ARCA biopharma Competitors include CRISPR Therapeutics, Ultragenyx Pharmaceutical, Vical and Sarepta Therapeutics.
Add company...
ARCA biopharma
ARCA biopharma
ARCA biopharma develops genetically-targeted therapies for cardiovascular diseases.
CRISPR Therapeutics
CRISPR Therapeutics
CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Vical
Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies.
Sarepta Therapeutics
Sarepta Therapeutics
Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics.
Founding Date
Founding Date
2009
Founding Date
2013
Founding Date
2010
Founding Date
1987
Founding Date
1980
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Westminster, US HQ
Westminster, US
Aurora, US
Locations
Zug, CH HQ
Greater London, GB
Cambridge, US
Locations
Novato, US HQ
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Employees
Employees
20
Employees
93
Employees
376
Employees
74
Employees
197
Valuation ($)
Valuation ($)
5.5 m
Valuation ($)
1.6 b
Valuation ($)
2.9 b
Valuation ($)
21.6 m
Valuation ($)
9.3 b
Twitter followers
Twitter followers
N/A
Twitter followers
3.5 k
Twitter followers
N/A
Twitter followers
65
Twitter followers
302

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$2.6m (FY, 2017)
Revenue (est.)
$13.8m (FY, 2017)
Revenue (est.)
$154.6m (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$1k (FY, 2017)
Cost of goods
N/A
Cost of goods
$7.4m (FY, 2017)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$2.6m (FY, 2017)
Gross profit
N/A
Gross profit
$147.2m (FY, 2017)
Net income
Net income
($18.5m) (FY, 2017)
Net income
($68.4m) (FY, 2017)
Net income
($302.1m) (FY, 2017)
Net income
($13m) (FY, 2017)
Net income
($50.7m) (FY, 2017)

Funding

Total funding raised
Total funding raised
$ 7.2m
Total funding raised
$ 127m
Total funding raised
$ 200.1m
Total funding raised
N/A
Total funding raised
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles

CRISPR Therapeutics
HQ
Zug, CH
Employees
93

CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.

View company
Ultragenyx Pharmaceutical
HQ
Novato, US
Employees
376

Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.

View company
Vical
HQ
San Diego, US
Employees
74

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies.

View company
Sarepta Therapeutics
HQ
Cambridge, US
Employees
197

Sarepta Therapeutics is a biopharmaceutical company focused on developing innovative RNA-targeted therapeutics.

View company